Xenon Pharmaceuticals Stock Income Statements

Xenon Pharmaceuticals Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Operating Profit

Net Income

Xenon Pharmaceuticals Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30

collaboration revenue		7,500,000																													15,000	264,000	15,000	15,000	374,000	412,000	412,000	569,000	3,226,000	4,293,000	4,044,000	4,010,000	4,877,000	13,192,000
operating expenses:
research and development	74,985,000	61,200,000	59,472,000	56,970,000	49,702,000	44,250,000	41,076,000	42,880,000	44,040,000	39,516,000	34,830,000	29,431,000	22,146,000	19,360,000	21,887,000	18,891,000	18,377,000	16,308,000	14,967,000	13,045,000	10,720,000	11,791,000	11,752,000	9,751,000	8,205,000	9,137,000	6,406,000	6,240,000	5,408,000	5,580,000	6,397,000	7,164,000	6,109,000	5,903,000	4,396,000	5,965,000	5,103,000	4,364,000	4,263,000	3,793,000	3,669,000	3,427,000	3,453,000	3,216,000
general and administrative	19,244,000	19,038,000	18,005,000	16,706,000	19,402,000	14,791,000	12,619,000	12,804,000	11,584,000	9,535,000	8,501,000	8,829,000	8,705,000	6,775,000	6,688,000	4,831,000	6,339,000	4,109,000	3,106,000	3,208,000	3,310,000	3,320,000	3,175,000	2,700,000	2,307,000	2,621,000	2,028,000	1,938,000	2,178,000	2,238,000	1,670,000	1,744,000	1,799,000	2,100,000	1,442,000	1,779,000	1,676,000	1,895,000	1,567,000	1,321,000	2,058,000	1,789,000	1,390,000	1,316,000
total operating expenses	94,229,000																																										3,105,250	4,532,000
income from operations	-94,229,000	-72,738,000	-77,477,000	-73,676,000	-69,104,000	-59,041,000	-53,695,000	-55,684,000	-55,624,000	-49,051,000	-43,331,000	-38,128,000	-30,315,000	-17,369,000	-24,838,000	-15,598,000	-22,498,000	-16,059,000	-12,923,000	-9,699,000	-646,000	-8,033,000	-11,598,000	-8,951,000	-10,512,000	-11,758,000	-8,434,000	-14,178,000	-7,586,000	-7,818,000	-8,051,000	-8,644,000	-7,893,000	-7,987,000	-5,462,000	-7,331,000	-6,366,000	-5,658,000	-2,603,000	-820,000	199,000	-1,206,000	35,000	8,661,000
yoy	36.36%	23.20%	44.29%	32.31%	24.23%	20.37%	23.92%	46.04%	83.49%	182.41%	74.45%	144.44%	34.75%	8.16%	92.20%	60.82%	3382.66%	99.91%	11.42%	8.36%	-93.85%	-31.68%	37.51%	-36.87%	38.57%	50.40%	4.76%	64.02%	-3.89%	-2.12%	47.40%	17.91%	23.99%	41.16%	109.83%	794.02%	-3298.99%	369.15%	-7537.14%	-109.47%
qoq	29.55%	-6.12%	5.16%	6.62%	17.04%	9.96%	-3.57%	0.11%	13.40%	13.20%	13.65%	25.77%	74.54%	-30.07%	59.24%	-30.67%	40.10%	24.27%	33.24%	1401.39%	-91.96%	-30.74%	29.57%	-14.85%	-10.60%	39.41%	-40.51%	86.90%	-2.97%	-2.89%	-6.86%	9.51%	-1.18%	46.23%	-25.49%	15.16%	12.51%	117.36%	217.44%	-512.06%	-116.50%	-3545.71%	-99.60%
operating margin %												-28884.85%	-5655.78%	-198.14%	-664.65%	-192.00%	-1014.34%	-368.49%	-250.93%	-147.99%	-4.83%	-113.49%	-348.39%	-255.74%
other income:
interest income	7,199,000	8,083,000	9,422,000	10,329,000	10,837,000	11,355,000	8,691,000	6,982,000	6,524,000	5,423,000	4,463,000	3,066,000	816,000	368,000	263,000	76,000	55,000	72,000	89,000	166,000	912,000	1,116,000	437,000	528,000	706,000	682,000	658,000	325,000	125,000	108,000	95,000	124,000	109,000	149,000	168,000	114,000	123,000	99,000	97,000	130,000	163,000	152,000	152,000	138,000
foreign exchange gain	1,698,000	35,000	-1,478,000	237,000	10,000	167,000	-90,000	-407,000	383,000	313,000	602,000	-2,381,000	-411,000	299,000	214,000	-128,000	117,000	155,000	497,000	475,000	662,000	-238,000	97,000	-80,000	135,000	130,000	-425,000	148,000	-140,000	-284,000	-109,000	778,000	404,000	321,000	-710,000	-497,000	227,000	2,296,000	-1,431,000	-3,137,000	806,000	-3,171,000	1,037,000	392,000
total other income	8,897,000
income before income taxes	-85,332,000	-64,620,000	-69,533,000	-63,110,000	-58,257,000	-47,519,000	-44,948,000	-48,619,000	-47,681,000	-41,437,000	-36,256,000	-37,737,000	-31,198,000	-20,064,000	-25,080,000	-15,650,000	-22,326,000	-15,832,000	-12,337,000	-9,058,000	-214,000	-7,485,000	-11,412,000	-8,866,000	-10,036,000	-11,304,000
income tax recovery	626,000		3,848,000	320,000	333,000		205,000	157,000	220,000		255,250	587,000	40,000	394,000	-484,000	205,000	217,000	68,000
net income	-84,706,000	-65,047,000	-65,685,000	-62,790,000	-57,924,000	-47,931,000	-44,743,000	-48,462,000	-47,461,000	-41,727,000	-37,395,000	-37,150,000																											-3,937,000	-3,827,000	1,168,000	-4,225,000	1,224,000	9,191,000
yoy	46.24%	35.71%	46.81%	29.57%	22.05%	14.87%	19.65%	30.45%																															-421.65%	-141.64%
qoq	30.22%	-0.97%	4.61%	8.40%	20.85%	7.13%	-7.67%	2.11%	13.74%	11.58%	0.66%																												2.87%	-427.65%	-127.64%	-445.18%	-86.68%
net income margin %												-28143.94%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
other comprehensive income:
unrealized gain on available-for-sale securities	949,000	776,000	-2,948,000	3,548,000		-1,692,000	2,876,000	346,000		1,180,000
comprehensive loss	-83,757,000	-64,271,000	-68,633,000	-59,242,000	-58,367,000	-49,623,000	-41,867,000	-48,116,000	-48,940,000	-40,547,000	-37,440,000	-39,115,000
net income per common share
basic and diluted	-1,070	-830	-840	-810	-750	-620	-640	-730	-720	-630	-570	-570	-550	-350	-480	-360	-510	-420	-340	-250	0	-220	-410	-330	-370										-290	-510		-230				-300
weighted-average common shares outstanding
basic and diluted	78,953,445,000	78,687,503,000	77,894,643,000	77,926,205,000	77,671,128,000	77,594,599,000	66,889,005,000	66,002,163,000	65,861,138,000	65,724,681,000	60,542,142,000	65,465,069,000	56,192,922,000	54,852,792,000	43,627,452,000	41,193,267,000	43,106,207,000	36,824,619,000	34,542,213,000	34,994,944,000		33,189,733,000	25,939,405,000	25,793,482,000												15,268,964,000		14,394,000,000				14,212,579,000
income tax expense		-427,000				-412,000																				-37,000
unrealized fair value gain on trading securities							146,000	490,000	1,036,000	1,878,000	2,010,000	-294,000
other comprehensive loss:
unrealized loss on available-for-sale securities					-443,000				-1,479,000
revenue												132,000	536,000	8,766,000	3,737,000	8,124,000	2,218,000	4,358,000	5,150,000	6,554,000	13,384,000	7,078,000	3,329,000	3,500,000
yoy												-98.38%	-75.83%	101.15%	-27.44%	23.95%	-83.43%	-38.43%	54.70%	87.26%
qoq												-75.37%	-93.89%	134.57%	-54.00%	266.28%	-49.11%	-15.38%	-21.42%	-51.03%	89.09%	112.62%	-4.89%
net income attributable to preferred shareholders											-17,000			-299,000	-487,000	-362,000	-521,000	-423,000	-350,000	-250,000	-5,000	-222,000	-422,000	-336,000	-380,000	-430,000	-375,000	-1,621,000	-1,303,000	-33,000
net income attributable to common shareholders							-44,743,000	-48,462,000	-47,461,000	-41,727,000	-37,378,000	-37,150,000	-31,158,000	-19,371,000	-25,077,000	-15,083,000	-21,588,000	-15,341,000	-11,973,000	-8,605,000	-170,000	-7,262,000	-10,954,000	-8,535,000	-9,627,000	-10,911,000	-8,183,000	-12,762,000	-6,498,000	-3,722,000									-3,937,000	-3,827,000	1,168,000	-4,225,000	9,423,000	3,595,000
income tax (expense) recovery										-290,000
unrealized losses on available-for-sale securities											-491,250	-1,965,000
unrealized fair value loss on marketable securities													-1,288,000	-3,362,000
net income and comprehensive loss													-31,158,000	-19,670,000	-25,564,000	-15,445,000	-22,109,000	-15,764,000	-12,323,000	-8,855,000	-175,000	-7,484,000	-11,376,000	-8,871,000	-10,007,000	-11,341,000	-8,558,000	-14,383,000	-7,801,000	-3,755,000	-8,065,000	-7,742,000	-7,380,000	-7,517,000	-4,248,250	-7,714,000		-3,263,000
interest expense																					-154,000	-330,000	-348,000	-363,000	-365,000	-358,000	-357,000	-678,000	-200,000	-159,000
loss on repayment of term loan																					-988,000
income tax																			60,750	203,000	39,000	1,000	-3,250	-5,000	29,000
weighted-average common shares outstanding
basic																					34,979,282,000				25,773,879,000	25,753,836,000	19,425,711,000	20,306,298,000	14,306,491,000	17,804,421,000	17,985,061,000	17,998,420,000	17,997,194,000	17,946,209,000	15,493,474,000		14,408,108,000		14,281,837,000	14,298,612,000	14,241,827,000		3,165,572,000	1,348,417
diluted																					34,979,282,000				25,775,559,000	25,753,836,000	19,425,711,000	20,306,298,000	14,306,491,000	17,804,421,000	18,001,759,000	18,009,979,000	18,015,748,000	17,974,469,000			14,434,602,000				15,129,978,000
buy-out of future milestones and royalties																												6,000,000
gain on termination of collaboration agreement																														4,398,000
net income per common share
basic																										-420	-290	-630	-450	-210	-450	-430	-410	-420			-420		-270	-270	80		4,107.33	2.67
diluted																										-420	-290	-630	-450	-210	-450	-430	-410	-430			-420		-270	-270	-70		3,278.29	1.69
revenue:
royalties																															1,000			1,000	2,000	1,000	1,000	32,000	1,000	1,000	2,000		1,000	1,000
net income and comprehensive income																																					-6,016,000
weighted-average shares outstanding
basic and diluted	78,953,445,000	78,687,503,000	77,894,643,000	77,926,205,000	77,671,128,000	77,594,599,000	66,889,005,000	66,002,163,000	65,861,138,000	65,724,681,000	60,542,142,000	65,465,069,000	56,192,922,000	54,852,792,000	43,627,452,000	41,193,267,000	43,106,207,000	36,824,619,000	34,542,213,000	34,994,944,000		33,189,733,000	25,939,405,000	25,793,482,000												15,268,964,000		14,394,000,000				14,212,579,000
net income attributable to participating securities																																											2,049,750	5,596,000
weighted-average shares outstanding
basic																					34,979,282,000				25,773,879,000	25,753,836,000	19,425,711,000	20,306,298,000	14,306,491,000	17,804,421,000	17,985,061,000	17,998,420,000	17,997,194,000	17,946,209,000	15,493,474,000		14,408,108,000		14,281,837,000	14,298,612,000	14,241,827,000		3,165,572,000	1,348,417
effects of dilutive securities
stock options																																											797,475,033	763,949
subscription rights																																											2,861.75	10,400
diluted																																							30,831,000	14,298,612,000			3,961,688,597	2,122,766
foreign currency translation adjustment
comprehensive income																																							-3,937,000	-3,827,000	1,168,000	-4,225,000
general and administrative - stock based compensation																																									-1,880,000
weighted-average shares outstanding
basic																					34,979,282,000				25,773,879,000	25,753,836,000	19,425,711,000	20,306,298,000	14,306,491,000	17,804,421,000	17,985,061,000	17,998,420,000	17,997,194,000	17,946,209,000	15,493,474,000		14,408,108,000		14,281,837,000	14,298,612,000	14,241,827,000		3,165,572,000	1,348,417
diluted																					34,979,282,000				25,775,559,000	25,753,836,000	19,425,711,000	20,306,298,000	14,306,491,000	17,804,421,000	18,001,759,000	18,009,979,000	18,015,748,000	17,974,469,000			14,434,602,000				15,129,978,000
net income per common share:
basic and diluted	-1,070	-830	-840	-810	-750	-620	-640	-730	-720	-630	-570	-570	-550	-350	-480	-360	-510	-420	-340	-250	0	-220	-410	-330	-370										-290	-510		-230				-300
weighted-average shares outstanding:
basic and diluted	78,953,445,000	78,687,503,000	77,894,643,000	77,926,205,000	77,671,128,000	77,594,599,000	66,889,005,000	66,002,163,000	65,861,138,000	65,724,681,000	60,542,142,000	65,465,069,000	56,192,922,000	54,852,792,000	43,627,452,000	41,193,267,000	43,106,207,000	36,824,619,000	34,542,213,000	34,994,944,000		33,189,733,000	25,939,405,000	25,793,482,000												15,268,964,000		14,394,000,000				14,212,579,000
gain on write-off and disposal of assets
net income per share
basic																										-420	-290	-630	-450	-210	-450	-430	-410	-420			-420		-270	-270	80		4,107.33	2.67
diluted																										-420	-290	-630	-450	-210	-450	-430	-410	-430			-420		-270	-270	-70		3,278.29	1.69
weighted-average shares outstanding:
basic																					34,979,282,000				25,773,879,000	25,753,836,000	19,425,711,000	20,306,298,000	14,306,491,000	17,804,421,000	17,985,061,000	17,998,420,000	17,997,194,000	17,946,209,000	15,493,474,000		14,408,108,000		14,281,837,000	14,298,612,000	14,241,827,000		3,165,572,000	1,348,417
effects of dilutive securities:

We provide you with 20 years income statements for Xenon Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Xenon Pharmaceuticals stock. Explore the full financial landscape of Xenon Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Xenon Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.